![Mary Reumuth](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mary Reumuth
Director Financiero/CFO en KALA BIO, INC. .
Fortuna: 488 571 $ al 31/05/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 8 años |
Howard Rosen | M | 66 | 10 años | |
Jon Aron Olof Heimer | M | 57 | 4 años | |
Mark Iwicki | M | 57 | 9 años | |
Andrew Koven | M | 66 | 7 años | |
Solange Bullukian | F | 59 | 3 años | |
Carl Raimond | M | 53 | 4 años | |
Fredrik Netzel | M | 55 | 5 años | |
Johan Lund | M | 67 | 4 años | |
Marjan Farid | M | 50 | 2 años | |
Rickard El Tarzi | M | - | 5 años | |
Gregory Perry | M | 63 | 6 años | |
Todd Bazemore | M | 53 | 7 años | |
Tommi Markus Unkuri | M | 44 | 5 años | |
Robert Schueren | M | 62 | 2 años | |
Mark Blumenkranz | M | 73 | 3 años | |
Charles Myers | M | 70 | 3 años | |
Jon Hindar | M | 68 | 3 años | |
Nicolas Roelofs | M | 66 | 6 años | |
Darius Kharabi | M | 45 | 3 años | |
Anna Maria Marsell | F | 46 | 2 años | |
Hannah Deresiewicz | F | - | - | |
Gregory Moore | M | 59 | 1 años | |
Oskar Hjelm | M | 39 | 4 años | |
Ida Grundberg | M | 41 | 5 años | |
Romulus Brazzell | M | 71 | 11 años | |
Linda Ramirez-Eaves | F | 52 | 5 años | |
Bruno Rossi | M | - | 1 años | |
Johan Holmner | M | - | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
James Levine | M | 53 | - | |
Janet Skogan Roemer | F | 68 | 6 años | |
Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 años |
Alexander Fitzpatrick | M | 57 | 4 años | |
Paulina Hill | M | 42 | 1 años | |
Charles McDermott | M | 52 | 4 años | |
Tina Nova | M | 70 | 1 años | |
Raj Shah | M | 46 | 6 años | |
Robert Paull | M | 47 | - | |
Gregory Grunberg | M | 51 | 7 años | |
Gerald M. Haines | M | 61 | 2 años | |
Robert Langer | M | 74 | 9 años | |
Gustavo Salem | M | 60 | 3 años | |
Robert Tepper | M | 68 | 9 años | |
John F. Dee | M | 66 | 5 años | |
Steven Zhang | M | - | - | |
Chen-Ming Yu | M | 50 | 1 años | |
Vincent Kosewski | M | - | - | |
Barbara Littlefield | F | 66 | 4 años | |
James Patnoe | M | - | - | |
Susan L. Coultas | M | - | 6 años | |
John Miller | M | - |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 años |
Kathleen McCann Kline | F | - | - | |
Michele LaRussa | F | 54 | - | |
Niranjan Kameswaran | M | - | - | |
John R. Malloy | M | 65 | 2 años | |
Stephen P. Toon | M | - | 2 años | |
Gregory Powers | M | - | 2 años | |
Julie Smith | F | 53 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 4 años |
Geoffrey Peter Hazlewood | M | 73 | 7 años | |
Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 años |
Kevin Bitterman | M | 47 | - | |
Kevin R. Bracken | M | 75 | - | |
Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 años |
John A. McCarthy | M | 65 | 1 años | |
Melvin I. Simon | M | 85 | 14 años | |
Mark Leschly | M | 55 | 10 años | |
William Baum | M | 79 | 13 años | |
Simon B. Rich | M | 80 | 3 años | |
Josiah Craver | M | - | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 45 | 65.22% |
Suecia | 19 | 27.54% |
Canadá | 6 | 8.70% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Mary Reumuth
- Red Personal